Latest: FDA Approves New Biosimilar for Oncology Treatment
Healthcare Business

Two Patients With Non-Hodgkin Waldenstrom Lymphoma See Complete Responses With CD19 CAR-NK Immunotherapy, ImmunityBio Reports

by American Journal Managed Care
0 Comments
0 Mins
ImmunityBio's study reveals promising results for chemotherapy-free CD19 CAR NK cell therapy in treating Waldenström macroglobulinemia, offering hope for patients.
Tags:
American Journal Managed Care
Author

American Journal Managed Care

Previous Post
Even Low Disease Activity Has QOL Impact in Myasthenia Gravis
Next Post
Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago